This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. TRIB, VRAX, AWH, TNFA, MYMD, NAVB, IDXX, LNTH, QDEL, and CLDXShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include Trinity Biotech (TRIB), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), Lantheus (LNTH), QuidelOrtho (QDEL), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector. Akers Biosciences vs. Trinity Biotech Virax Biolabs Group Aspira Women's Health TNF Pharmaceuticals MyMD Pharmaceuticals Navidea Biopharmaceuticals IDEXX Laboratories Lantheus QuidelOrtho Celldex Therapeutics Trinity Biotech (NASDAQ:TRIB) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do institutionals and insiders believe in TRIB or AKER? 79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 5.5% of Akers Biosciences shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 0.3% of Akers Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor TRIB or AKER? Trinity Biotech received 28 more outperform votes than Akers Biosciences when rated by MarketBeat users. However, 72.92% of users gave Akers Biosciences an outperform vote while only 70.23% of users gave Trinity Biotech an outperform vote. CompanyUnderperformOutperformTrinity BiotechOutperform Votes33570.23% Underperform Votes14229.77% Akers BiosciencesOutperform Votes30772.92% Underperform Votes11427.08% Which has higher valuation and earnings, TRIB or AKER? Akers Biosciences has lower revenue, but higher earnings than Trinity Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$59.13M0.26-$24.02M-$2.26-0.37Akers Biosciences$1.58M2.12-$3.89MN/AN/A Which has more volatility & risk, TRIB or AKER? Trinity Biotech has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Is TRIB or AKER more profitable? Akers Biosciences has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Akers Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-34.39% N/A -21.37% Akers Biosciences N/A -87.42%-73.31% Does the media refer more to TRIB or AKER? In the previous week, Trinity Biotech had 2 more articles in the media than Akers Biosciences. MarketBeat recorded 2 mentions for Trinity Biotech and 0 mentions for Akers Biosciences. Trinity Biotech's average media sentiment score of 0.50 beat Akers Biosciences' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media. Company Overall Sentiment Trinity Biotech Positive Akers Biosciences Neutral SummaryTrinity Biotech beats Akers Biosciences on 9 of the 13 factors compared between the two stocks. Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.35M$2.62B$5.57B$8.05BDividend YieldN/A0.75%5.36%4.22%P/E RatioN/A7.7922.8119.02Price / Sales2.1250.78406.34107.05Price / CashN/A15.7538.1834.62Price / Book0.043.796.794.34Net Income-$3.89M-$65.73M$3.23B$248.27M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.20+0.0%N/A-94.0%$3.35M$1.58M0.004Gap UpHigh Trading VolumeTRIBTrinity Biotech1.2573 of 5 stars$0.56+1.5%N/A-53.4%$10.07M$59.13M-0.25480Short Interest ↓VRAXVirax Biolabs Group1.6967 of 5 stars$0.91-8.1%$3.00+228.6%+65.3%$2.95M$84,872.000.005Gap UpAWHAspira Women's Health1.5836 of 5 stars$0.08-12.5%$5.50+6,607.3%-97.4%$2.44M$9.18M-0.07110High Trading VolumeTNFATNF PharmaceuticalsN/A$0.17-6.4%N/AN/A$1.86MN/A-0.016Gap DownHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.18-25.4%N/A-94.0%$434,000.00N/A0.006Positive NewsHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/AN/A$60,000.00$8,126.000.0010Analyst ForecastNews CoverageIDXXIDEXX Laboratories4.5037 of 5 stars$406.65-1.2%$523.75+28.8%-1.8%$32.95B$3.90B38.1110,800Upcoming EarningsAnalyst ForecastPositive NewsLNTHLantheus3.9721 of 5 stars$100.62-0.7%$129.43+28.6%+44.0%$6.89B$1.53B16.74700Upcoming EarningsAnalyst RevisionPositive NewsQDELQuidelOrtho4.5732 of 5 stars$24.56-2.4%$46.83+90.7%-31.5%$1.66B$2.78B-0.817,000Upcoming EarningsAnalyst RevisionNews CoverageCLDXCelldex Therapeutics1.7509 of 5 stars$18.94+3.5%$54.33+186.9%-51.5%$1.26B$7.02M-7.37150Earnings ReportUpcoming EarningsAnalyst ForecastNews Coverage Related Companies and Tools Related Companies Trinity Biotech Alternatives Virax Biolabs Group Alternatives Aspira Women's Health Alternatives TNF Pharmaceuticals Alternatives MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives IDEXX Laboratories Alternatives Lantheus Alternatives QuidelOrtho Alternatives Celldex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKER Stock Free AKER Stock Alerts